What is known and objective: Obesity is a significant burden on the healthcare system in the United States, and determining the appropriate antimicrobial dosing regimen in morbidly obese patients is challenging. Morbidly obese patients have documented differences in pharmacokinetic and pharmacodynamic properties compared to normal-weight patients, which impact antibiotic efficacy and toxicity. The Food and Drug Administration does not recognize obesity as a special population and does not require pharmaceutical companies to perform studies specific to obese patients. However, there are an increasing number of post-approval studies in obese patients, and this manuscript reviews available clinical and pharmacokinetic literature regarding weight-based antimicrobial agents. Additionally, we describe a single-centre approach to optimize dosing in morbidly obese patients. Methods: A comprehensive literature search was performed on 15 weight-based antimicrobials in the setting of obesity: acyclovir, aminoglycosides, amphotericin B, cidofovir, colistimethate, daptomycin, flucytosine, foscarnet, ganciclovir, quinupristin/ dalfopristin, trimethoprim/sulfamethoxazole, vancomycin and voriconazole. A weight-based antimicrobial dosing guideline for morbidly obese patients was developed. An analysis of guideline compliance and cost analysis were performed following guideline implementation. Results and discussion: This review describes the pharmacokinetic changes that occur in obese patients, including increased volume of distribution, altered hepatic metabolism, renal excretion and changes in protein binding. The majority of weightbased antimicrobials result in increased serum concentrations in morbidly obese patients compared to normal-weight patients when the calculated dose is based on actual body weight. What is new and conclusion: This review demonstrates different antibiotic pharmacokinetic properties are altered in obese patients that could impact efficacy and toxicity. A single-centre guideline for weight-based antimicrobial dosing in obesity was developed and provides recommendations for using ideal body weight, adjusted body weight or actual body weight when calculating antimicrobial doses. However, more research is needed to better elucidate optimal dosing of weight-based antimicrobials in obesity, with particular focus on efficacy and toxicity.
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WHAT IS KNOWN AND OBJECTIVE
Obesity is a major issue in the United States, with 78 million US adults and 12Á5 million children and adolescents classified as obese [body mass index (BMI) greater than or equal to 30] . 1 This equates to an obesity rate of 35% and 16Á9% in adults and children in the United States, respectively. 1 Physiological changes in obesity can alter immunological pathways and increase the risk of central line infection, post-operative surgical site infections, intensive care unit length of stay and risk for severe pneumonia and influenza. [2] [3] [4] [5] Additionally, changes in antimicrobial pharmacokinetic and pharmacodynamic properties are well documented, which impact clinical success and risk of toxicity. [2] [3] [4] [5] Despite the unique characteristics of the obese patient population, the Food and Drug Administration does not require pharmaceutical manufacturers to evaluate dosing recommendations in obesity. Calculating a weight-based antibiotic regimen is particularly concerning, as most antimicrobials do not significantly penetrate adipose tissue which results in increased serum concentrations in morbidly obese patients. [2] [3] [4] [5] Some studies recommend using ideal body weight (IBW) or adjusted body weight (AdjBW) when calculating an antimicrobial dose in morbidly obese patients to strike a balance between obtaining adequate serum antibiotic concentration to effectively treat an infection while attempting to minimize potential toxicities (Table 1) . [2] [3] [4] [5] [6] Weight-based antimicrobials in this review include acyclovir, aminoglycosides, amphotericin B, cidofovir, colistimethate, daptomycin, flucytosine, foscarnet, ganciclovir, quinupristin/dalfopristin, trimethoprim/sulfamethoxazole, vancomycin and voriconazole. General dosing recommendations in obesity are provided for each agent reviewed; however, the clinician must balance toxicity with efficacy on a case-by-case basis to avoid treatment failure and promotion of antimicrobial resistance. Evaluation of compliance rates and cost savings are analysed following implementation of weight-based antimicrobial dosing recommendations in morbidly obese patients at the University of Michigan Hospitals and Health System (UMHS). absorption can occur in obesity secondary to delays in gastric emptying, likely caused by differences in dietary habits compared to non-obese subjects. 6 Drug absorption is also delayed or incomplete following subcutaneous injections in morbid obesity. Intramuscular injections may also inadvertently be given as a deep subcutaneous injection due to increased quantity of adipose tissue. 6 The volume of distribution (V d ) in obesity can be dramatically different compared to normal-weight patients. 2, 4, 5 The extent of change of drug distribution is primarily based on its intrinsic characteristics such as molecular size, degree of ionization, extent of lipid solubility, protein binding and ability to cross biological membranes. 7 Obesity does not significantly alter albumin binding of medications but may have alterations in lipoproteins and alpha1-acid glycoprotein although studies are inconclusive. 8, 9 Other physiological changes, such as tissue blood flow and changes in cardiac output, can also alter drug distribution, although the significance of these changes is yet to be determined. 6, 7 Physiological changes in the liver and kidneys of obese patients can alter metabolism and excretion. 2, 4 The increased presence of fatty infiltration in the liver can alter blood flow and thus drug metabolism. 6, 7 Additionally, level of cytochrome P450 pathway activity might be altered in obese patients. One study demonstrated increased activity of CYP2E1 and reduced CYP3A4 in obesity, with trends towards change with other CYP isozymes. 9 Obesity can increase glomerular filtration rate (GFR), but this observation is primarily associated with otherwise healthy patients. 2 Obesity in the presence of other comorbidities, especially hypertension, can increase the risk for chronic renal dysfunction. 2 A study conducted in healthy obese patients utilizing common equations for evaluating creatinine clearance or estimated GFR showed both overestimation and underestimation when compared to measured GFR, which can impact the dose and frequency of antimicrobials. 10 Similarly, obese patients in intensive care units may have larger fluctuations in beta-lactam serum concentrations.
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REVIEW OF ANTIMICROBIAL AGENTS
Aminoglycosides
Pharmacokinetics of amikacin, gentamicin and tobramycin in obesity are well documented and described in at least 11 human studies (Table 3 ). Most studies demonstrate a need for dose adjustments in obesity and recommend use of AdjBW. The recommended correction factor varied slightly among studies, which is likely the result of different patient populations and dosing regimens. 2, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Nine studies recommend AdjBW with adjustments ranging from 0Á20 to 0Á58 [IBW plus 20-58% difference between actual body weight (ABW) and IBW]. 2, 12, 13, [15] [16] [17] [18] 20, 21 Only one study did not find a difference in pharmacokinetics between obese and normal-weight patients. 19 This study examined gentamicin and tobramycin in 27 obese peri-partum women and was underpowered to demonstrate statistical significance.
The available literature evaluating aminoglycoside dosing in obesity often has small sample sizes, includes single-dose pharmacokinetic studies and rarely assesses safety. However, the results largely support the use of AdjBW when dosing aminoglycosides in obesity, often with a weight of IBW plus approximately 40% of the excess body weight. Additionally, obesity recommendations are provided in the tobramycin prescribing information, which recommends use of AdjBW [lean body weight (LBW) plus 40% of the excess body weight] when calculating a dosing regimen. 22 
Colistimethate
Colistimethate studies in obesity are described in three retrospective studies, one prospective study and one case report. [23] [24] [25] [26] [27] A prospective study by Garonzik et al. 26 examined pharmacokinetics of colistimethate in approximately 100 patients with doses ranging from 75 to 410 mg daily. A linear pharmacokinetic model was • Single-dose pharmacokinetic study • Adult, obese patients with >50%
excess weight treated with gentamicin for bacterial infections compared to normal-weight patients
• Gentamicin 0Á8-1Á3 mg/kg (capped at 120 mg)
• n = 17
• Uptake of gentamicin in adipose tissue found to be 43Á7% of uptake in ABW of normal-weight patients
• Average apparent V d in obese and normal patients was 17Á7% and 23Á0%, respectively
• Serum half-life values in obese and normal-weight groups unchanged
• Three patients were excluded due to baseline abnormal serum creatinine
• Authors recommend using AdjBW to determine proper gentamicin dose
• AdjBW = (ABW À IBW) 9
43
Á7%
+ IBW
Aminoglycoside dosing in obese puerperal women Gibbs (1985) • Non-randomized, prospective study
• Obese puerperal women (ABW 30% larger than desirable weight) treated for endometritis
• Dosed with 1Á5 mg/kg every 8 h, with one group dosed based on AdjBW and another group dosed on ABW (capped at 150 mg per dose)
• n = 27
• Average peak serum concentration of 4Á7 and 5Á5 lg/mL in adjusted and non-adjusted dosing groups, respectively (non-significant different, P-value not reported)
• (P ≤ 0Á008 for obese and overweight compared to normal-weight subjects on tobramycin and compared to obese subjects on gentamicin)
• V d relative to ABW: 0Á35, 0Á33 and 0Á30 L/kg for tobramycin and 0Á35, 0Á32 and 0Á27 L/kg for gentamicin in normal-weight, overweight and obese patients, respectively (P ≤ 0Á008 for obese and overweight compared to normal-weight subjects on gentamicin and compared to obese subjects on tobramycin)
• Not addressed
• Aminoglycoside dosing can be simplified across all weight strata with use of LBW (continued) 
Safety
Conclusions
A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects Schwartz (1978) • Single-dose kinetics study • Obese and normal subjects given tobramycin or gentamicin at 1 mg/ kg (120 mg dose cap)
• Indices adjusted to give normal subjects mean adiposity index of
1Á0
• n = 26
• Gentamicin V d relative to ABW was 185 and 244 mL/kg for obese and normal patients, respectively (P < 0Á05)
• Gentamicin V d relative to AdjBW was 248 and 244 mL/kg for obese and normal patients, respectively (not significant at 0Á05 level)
• Gentamicin V d relative to normalized body weight was 337 and 244 mL/kg for obese and normal patients, respectively (P < 0Á05)
• • Equations developed to predict normal weight as sum of lean and fat body mass using normal-sized adult oncology patients; predicted normal weight descriptor assessed • Open-label population pharmacokinetic study • Retrospective cohort study • Patients that received IV colistin for
• Nephrotoxicity occurred in 43% of patients, and these patients received higher doses than those who did not develop nephrotoxicity (5Á3 mg/kg/day IBW vs. 3Á95 mg/kg/day IBW, P < 0Á001)
• Statistically significant trend between increasing dosage of colistin and frequency of developing nephrotoxicity (P < 0Á001 for creatinine clearance >50 and creatinine clearance 30-49; P = 0Á01 for creatinine clearance <30 mL/min)
• • Open-label, single-dose, parallelgroup study of pharmacokinetics • Absolute V d of 11Á3 and 7Á4
(P < 0Á001) in morbidly obese and non-obese subjects, respectively
• Weight-normalized (ABW) CL of 7Á8 and 10Á2 mL/h/kg (P = 0Á045) in morbidly obese and non-obese subjects, respectively • Discontinued in 3 patients with musculoskeletal effects
• CPK levels returned to normal during treatment or within the post-treatment follow-up period for six patients with elevated CPK
• Daptomycin • n = 48
• Good correlation between ABW and clearance (r = 0Á948, P < 0Á0001)
• V d 0Á32 and 0Á68 L/kg ABW in obese and non-obese, respectively
• Half-life of 3Á3 and 7Á2 h in obese and non-obese patients, respectively
• Not addressed developed using serum colistin methanesulfonate concentrations and suggested only the loading dose should be weight based. Nearly half of the patients had an increase in serum creatinine of over 50% from baseline, although the impact of weight was not examined on this safety measure. 25 Pogue et al. 23 assessed the incidence of and risk factors for colistimethate-associated nephrotoxicity in a large academic health system in 126 patients. Nephrotoxicity developed in 43% of patients and was associated with a higher mg/kg/day dose of colistimethate (relative to IBW). A statistically significant trend also existed between increasing overall dose and frequency of nephrotoxicity. These results weaken the argument to utilize ABW in dosing. A similar retrospective cohort study by Deryke et al. 24 in 30 patients found excessive colistimethate dosing was associated with higher rates of nephrotoxicity (80% vs. 30%, P = 0Á019).
Gauthier et al. 25 examined colistimethate in 42 overweight and obese individuals through a retrospective case-controlled study using doses based on prescribing information recommendations. Nearly half of the patients developed nephrotoxicity within a median of 5 days. A BMI of >31 kg/m 2 , age, diabetes and length of stay prior to colistimethate initiation were all independent risk factors for nephrotoxicity.
In summary, there are limited data comparing pharmacokinetics of colistimethate in obese vs. normal-weight patients. However, multiple studies demonstrate significant risk of nephrotoxicity with colistimethate in obese patients, and dosing based on IBW or AdjBW may be prudent, with infection severity driving the decision on a case-by-case basis.
Daptomycin
Daptomycin use in obese patients is assessed in six separate human trials and one case report. The drug is a large molecule (1620 Da), highly protein bound (90-95%), and has a fairly small V d (0Á1 L/kg) in healthy volunteers. 28 The prescribing information reports the plasma clearance of daptomycin as 15-23% lower in obese patients based on data from 12 obese or extremely obese patients, which is attributed to decreased renal function as opposed to obesity itself.
Pai et al. 29 performed a 4 mg/kg (based on ABW) single-dose pharmacokinetic study in 14 adult female morbidly obese and non-obese patients. The morbidly obese group yielded a 60% increase in C max (67Á3 vs. 42Á3 mg/L, P = 0Á029) and 60% increase in AUC (494 vs. 307 mg h/L, P = 0Á002) compared to the nonobese group. The relationship of V d and total clearance with weight was best predicted by ABW (r 2 = 0Á66 and 0Á3, respectively) and BMI (r 2 = 0Á52 and 0Á24, respectively) when evaluated with linear regression.
Dvorchik et al. 30 also performed a single-dose pharmacokinetic evaluation of daptomycin in 25 obese and non-obese patients receiving 4 mg/kg based on ABW. C max and AUC 0-∞ increased by 25% and 30%, respectively, in morbidly obese compared to nonobese patients [average C max of 67 vs. 53 lg/mL (P = 0Á030), average AUC 0-∞ of 548 vs. 419 lg h/mL (P = 0Á004)]. Absolute V d increased 55% in morbidly obese relative to non-obese patients.
Bubalo et al. 31 examined the pharmacokinetics of daptomycin in 29 oncology patients with neutropenic fever. BMI ranged from 19 to 46 kg/m 2 , and daptomycin was dosed at 6 mg/kg ABW. Average daptomycin clearance decreased as BMI increased: 18Á93 AE 7Á24 mL/h/kg in normal-weight subjects, 14Á65 AE 3Á08 mL/h/kg in overweight subjects, 11Á86 AE 5Á16 mL/h/kg in obese subjects and 11Á41 AE 4Á29 mL/h/kg in morbidly obese subjects. This corresponds to an approximate 60% reduction in total body clearance in obese or morbidly obese patients relative to healthy subjects. A post hoc analysis showed a significant difference in clearance between normal-weight and obese subjects (P = 0Á015). No other pharmacokinetic parameters differed significantly by BMI. No patients experienced myopathy or required daptomycin to be discontinued due to elevated creatine phosphokinase (CPK) levels. The authors conclude a 6 mg/kg ABW dose every 24 h was both effective and well tolerated in adult oncology patients.
A case report was also published describing a 63-year-old severely obese male (BMI 81Á6 kg/m 2 ) treated with daptomycin, with dosing dictated by therapeutic drug monitoring. 32 The V d was anticipated to be approximately 0Á09 L/kg based on previous literature in obese patients, but the patient's V d was 0Á08 L/kg, with a C max of 57Á48 mg/L after a 1200 mg dose (4Á8 mg/kg ABW). CPK increased more than three times the baseline value by day 3 but normalized by day 7. In this case, the use of an adjusted dose resulted in reaching pharmacokinetic goals in an obese patient.
Two studies have demonstrated an increased risk of daptomycin myotoxicity in obese patients. 33, 34 A post hoc analysis following a phase 3 trial evaluating daptomycin vs. vancomycin in patients with Staphylococcus aureus bacteremia was performed by Bhavnani et al., 33 and they examined the incidence and risk factors for adverse events (i.e. elevations in CPK) in 108 patients receiving 6 mg/kg ABW every 24 h. They found CPK elevations in approximately 6% of patients, and risk factors for toxicity were obesity (ABW >110 kg) and daptomycin trough concentration >24Á3 mg/L. A multicentre retrospective cohort study by Bookstaver et al. 34 included 126 obese patients dosed by ABW for any indication and found CPK elevations of more than 1000 units/L in 8Á4% of patients and elevations of more than 500 units/L in nearly 14% of patients. Discontinuation of therapy due to adverse effects of daptomycin occurred in 6Á3% of patients, and the authors concluded there were increased CPK elevations in obesity with overall low rates of drug discontinuation.
Finally, Ng et al. 35 examined clinical efficacy of daptomycin dosing based on IBW vs. ABW, following an institutional guideline recommending daptomycin dosing based on IBW. They examined 107 patients treated with daptomycin 4-6 mg/kg with Enterococcus or Staphylococcus infection, with the primary outcome of clinical success (resolution of signs and symptoms of infection and/or no additional gram positive coverage from other antibiotics), or clinical improvement. No statistically significant differences were found between overall clinical and microbiological cure. No significant differences were seen in the number of adverse events in either dosing group; however, CPK levels were only available in 33% of the patients. Nonetheless, prescribing bias was likely present towards less severe infections within the IBW group, as more patients were treated for urinary tract infections.
In summary, there are prospective pharmacokinetic studies recommending the use of ABW, a retrospective study advocating the use of IBW, and a case report that promotes the use of AdjBW when dosing daptomycin in obese patients. Therefore, daptomycin dosing in obese patients based on IBW or AdjBW appears to have similar pharmacokinetics as normal-weight patients, similar efficacy, lower cost and lower risk of adverse effects. Although the rate of CPK elevation is relatively low, utilizing ABW in obese patients is a risk factor for toxicity. More studies are needed that focus on clinical efficacy and toxicity, and dosing should be determined in the context of infection severity and include close monitoring.
Quinupristin/dalfopristin
Quinupristin/dalfopristin pharmacokinetics in obesity have been examined in one single-dose pharmacokinetics study. In normal healthy patients, the V d for quinupristin is 0Á45 L/kg and for dalfopristin is 0Á24 L/kg. 36 Quinupristin has a molecular weight of 1022 Da while dalfopristin is 690 Da, and the per cent protein bound is higher for quinupristin than dalfopristin, although the general percentage is not reported in the package insert. Both compounds are primarily excreted in the faeces, likely through excretion in the bile. Despite the lack of data in obese patients, the prescribing information notes an increase in both C max and AUC by 30-40% in patients with a BMI ≥30 kg/m 2 , although no dose adjustments are suggested. A small study performed in 1997 found that both C max and AUC increased by 25% in obese patients (BMI > 30 kg/m 2 ) relative to non-obese patients after 7Á5 mg/kg of quinupristin/dalfopristin based on ABW. 37 Decisions regarding the appropriate weight to use for dosing should be made on a caseby-case basis while balancing risk vs. benefit and taking into consideration disease severity.
Sulfamethoxazole/trimethoprim
Sulfamethoxazole/trimethoprim pharmacokinetics in obesity have not been examined in human studies; however, one small human study in a related sulphonamide antibiotic, sulfisoxazole, has been performed. Sulfamethoxazole/trimethoprim is lipophilic, highly protein bound (70% for sulfamethoxazole, 44% for trimethoprim) and excreted primarily through the kidneys. 38 Both components are similarly small at 253 and 290 Da for sulfamethoxazole and trimethoprim, respectively.
A small study performed by Garrett et al. 39 examined pharmacokinetic properties of 1 g of IV sulfisoxazole, another sulphonamide antibiotic with similar pharmacokinetic properties to sulfamethoxazole, in four morbidly obese patients after jejunalileal bypass surgery. Pharmacokinetic parameters were collected after a single dose prescribed at 1 week presurgery and 1 week, 6 weeks, 6 months, and 12 months after surgery, and renal function remained stable throughout the study. Although up to 44% of body weight was lost after the first year, V d did not change, suggesting an obese individual may require a dose similar to a normal-sized individual -for weight-based dosing, this would involve using an AdjBW. Safety was not assessed.
Ultimately, without clinical data to support a specific dosing strategy, decisions regarding the appropriate weight to use for dosing should be made on a case-by-case basis. Monitoring for signs of clinical improvement and drug toxicity is crucial.
Vancomycin
Vancomycin pharmacokinetics in obesity are extensively examined in the literature. The drug is primarily eliminated via the kidneys, 55% bound to serum proteins, and V d ranges from 0Á3 to 0Á43 L/kg in normal-weight patients. 40 The prescribing information for vancomycin does not address its use in obese patients.
A retrospective matched study by Bauer et al. 41 examined vancomycin pharmacokinetics in 48 morbidly obese and nonobese patients. When normalized by ABW, clearance and V d did not differ between groups, but a reduced half-life was observed in the obese group. A study by Vance-Bryan et al.
42 assessed vancomycin concentrations in 230 patients stratified by body weight. ABW was a significant predictor for both V d , and multiple regression models showed ABW was superior to LBW when determining initial dosing requirements. Safety was not assessed in any of these retrospective studies. Finally, a case report by Penzak et al. 43 detailing a morbidly obese male with methicillin-resistant S. aureus foot ulcers treated with vancomycin showed ABW as opposed to IBW was more accurate in predicting the best dose for the patient in three of four dosing nomograms.
Blouin et al. published a prospective trial examining vancomycin dosing in obesity. In an uncontrolled, multiple-dose pharmacokinetic study, four non-obese patients were compared to six morbidly obese patients who received a single dose of vancomycin after gastric bypass. 44 Authors observed a strong positive correlation between ABW and both V d and clearance of vancomycin (correlation coefficient of 0Á94 and 0Á98, respectively). No significant difference in mg/kg daily dose required to reach the goal drug serum concentration of 15 lg/mL was noted between groups. These data support the use of ABW when dosing vancomycin in obese patients.
Another large retrospective study including 700 patients by Ducharme et al. 45 looked at the pharmacokinetics of vancomycin. V d adjusted for IBW was found to be greater in obese patients than in normal patients, and the authors noted that female gender, older age and obesity all resulted in higher V d through the use of regression equations. They recommend adjusting dose based on these factors. Another study by Leong et al. compared vancomycin clearance in overweight and obese patients to determine the best body weight measurement to use when dosing. However, only vancomycin troughs were available for assessment, and therefore, differences in V d were not able to be assessed. 46 The authors concluded AdjBW was the best predictor of vancomycin clearance and serum concentrations. Finally, a study by Reynolds et al. 47 compared doses and serum drug concentrations before and after a change in the institution's vancomycin dosing protocol. The protocol was changed from 15 mg/kg every 8-12 h to either 10 mg/kg every 12 h or 15 mg/kg every 24 h in obese patients. This resulted in a lower adjusted maintenance dose for obese patients of 19 mg/kg/day in the new protocol as opposed to 34 mg/kg/day in the prior protocol. The authors found an increase in frequency of target trough attainment and belowtarget attainment and a reduced frequency of supratherapeutic troughs. The revised protocol with lower total daily doses improved target trough attainment with minimal nephrotoxicity (1Á2%) utilizing ABW.
Vancomycin clearance and V d have been shown to increase in obese patients, which correspond with the need for increased doses in larger patients. However, a retrospective study by Heble et al. 48 in a group of obese and non-obese paediatric patients showed obesity to be an independent risk factor for elevated steady-state troughs when receiving equivalent doses by ABW. Presently, studies utilizing AdjBW provide insufficient data to support its use, although they have shown a correlation between AdjBW and Cockroft-Gault-predicted creatinine clearance, which can correlate to drug clearance. Overall, dosing vancomycin based on ABW is likely appropriate for initial dosing recommendations followed by therapeutic drug concentration monitoring, but obese patients may have reduced clearance and therapeutic drug monitoring of vancomycin trough levels is encouraged.
REVIEW OF ANTIFUNGAL AGENTS
Amphotericin B
Amphotericin B pharmacokinetics in obesity has been evaluated in four animal studies, but there is currently no published literature in humans (Table 4) . Amphotericin B has nonlinear kinetics, resulting in a large increase in serum levels compared to the magnitude of increase in dose. 49 The V d for liposomal amphotericin B is relatively small and ranges from 0Á1 to 0Á16 L/kg in hemopoetic stem cell transplant recipients and patients with cancer, which suggest limited drug distribution into adipose tissue.
Vadieie et al. 50 studied amphotericin B disposition in the hyperlipidemic Zucker rat compared to lean littermates. Serial blood samples were obtained after a single 1Á2 mg/kg dose and showed a twofold increase in AUC in obese rats. Weight-corrected V d and total body clearance were significantly lower in the obese rats. There was a significant decline in creatinine clearance from baseline in obese rats, whereas lean rats showed no difference in renal function.
Another study performed in non-infected rabbits by Groll et al. 51 examined amphotericin B concentrations in various body tissues after administration of different drug formulations, including amphotericin B deoxycholate, amphotericin B colloidal dispersion, amphotericin B lipid complex or liposomal amphotericin B. Compared to bone marrow and the liver, accumulation in fat tissue was relatively poor with concentrations being 22% or less than that found in liver or bone marrow for all formulations tested. Authors suggest dosing obese patients based on LBW accounting for expanded blood volume.
Two additional studies examined amphotericin B in hypercholesterolaemic rabbits. 52, 53 Ramaswamy et al. found that AUC was significantly higher and steady-state V d was significantly lower in cholesterol-fed rabbits relative to regular diet-fed rabbits. Significant increases in plasma creatinine levels were also observed in both diet groups. Koldin et al. saw no difference in rabbit survival rates or elevations of creatinine levels between groups when comparing normal and hypercholesterolaemic rabbits. Rabbits in both studies had similar ABW between groups but differences in serum cholesterol levels.
Prescribing information recommends weight-based doses ranging from 3 to 6 mg/kg/day depending on indication for liposomal and lipid-based products, but no recommended maximum dose is suggested and use in obesity is not addressed. 49 Animal studies demonstrate significant increase in amphotericin B serum concentration in obese rats and rabbits with poor lipid distribution and increased rates of nephrotoxicity. Use of IBW or AdjBW could be considered when determining doses for morbidly obese patients depending on the indication for use. More aggressive dosing could be warranted in certain situations, and the limitations of utilizing animal data for human dosing recommendations should be acknowledged.
Flucytosine
Flucytosine pharmacokinetics in obesity have been described in one case report. 54 Flucytosine is small (129 Da), only 3-4% protein bound and has a modest V d of approximately 0Á6 L/kg in normal patients. 49 A case report discusses a morbidly obese female who received 0Á3-0Á5 mg/kg/day IBW for treatment of extrameningeal cryptococcal infection with resolution of infection.
The patient had apparent CL of 1Á5 and 0Á71 mL/min/kg and V d of 0Á83 and 0Á4 L/kg relative to IBW and ABW, respectively. The authors recommend use of IBW as opposed to ABW as the examined pharmacokinetic parameters seemed to correlate best with non-obese patients when standardized to IBW. The use of ABW for flucytosine dosing in obese patients in the absence of robust clinical data may be prudent -given its V d -for initial dosing of life-threatening fungal infections, but therapeutic drug monitoring and individualized dosing are highly recommended. For non-life-threatening infections, doses based on IBW may be sufficient.
Voriconazole
Voriconazole pharmacokinetics in obesity have been examined in one small randomized trial, two retrospective studies and three case reports. The V d for voriconazole is 4Á6 L/kg and correlates with high tissue distribution. 55 The hepatic cytochrome P450 enzymes metabolize voriconazole and are the primary route of elimination. 55 Voriconazole metabolism is nonlinear, and serum concentrations are significantly increased following saturation of cytochrome P450 enzymes. Additionally, per cent plasma protein binding is 58%. The prescribing information recommends a loading dose of 6 mg/kg/dose IV every 12 h followed by 4 mg/ kg/dose IV or 200 mg PO every 12 h, but dosing in obesity is not specifically addressed.
In 2011, a randomized, crossover study was performed in 16 obese and non-obese patients (mean BMI 46 and 24 kg/m 2 , respectively). 56 Patients received either 400 mg of oral voriconazole every 12 h for two doses followed by 200 mg every 12 h for seven doses or 400 mg every 12 h for two doses followed by 300 mg every 12 h for seven doses. The authors found the V d and clearance of the drug to be similar between weight groups; however, AUC was 50% greater in obese patients. The study suggests the use of LBW over ABW when dosing voriconazole in obese patients.
Two retrospective studies conducted support the use of AdjBW for dosing voriconazole. A retrospective review by Koselke et al. 57 compared voriconazole levels in obese and nonobese patients when given 4 mg/kg ABW doses. A significantly higher voriconazole trough concentration was observed in obese patients compared to non-obese patients (6Á2 vs. 3Á5 mg/L, P > 0Á0001). The authors also compared dosing strategies in all obese patients who received dosing based on ABW, AdjBW and IBW. Mean serum trough concentrations in obese patients were 2Á7, 3Á2 and 6Á2 mg/L when dosed by IBW, AdjBW and ABW, respectively (P < 0Á0001). No obese patients dosed based on IBW or AdjBW experienced supratherapeutic levels. Therapeutic trough levels were achieved more often in patients dosed by IBW or AdjBW (60% and 67%, respectively) compared to ABW (28%). The authors concluded voriconazole should not be dosed based on ABW. 57 A retrospective chart review by DaviesVorbrodt et al. 58 examined patients on voriconazole with documented serum concentrations stratified by BMI. Random voriconazole serum levels were significantly higher in patients with BMI of 25 kg/m 2 or more compared to those with lower BMI. 58 The authors recommend use of AdjBW when dosing voriconazole in obese patients. 58 The use of AdjBW has also been recommended in three different case studies, with two patients poor voriconazole metabolizers. [59] [60] [61] Although available literature includes retrospective studies with small sample sizes, there is a strong association with Vadiei (1990) • Zucker hyperlipidemic obese rat model
• Serial blood samples after single IV infusion of amphotericin B (1Á2 mg/kg) in hyperlipidemic obese rats compared with lean litter mates
• n = 12
• AUC 15 600 vs. 7800 ng h/mL (P < 0Á05) in obese and lean litter rats, respectively
• No difference in elimination rate constants
kg and 4Á162 L/kg in obese and lean rats, respectively (P < 0Á05)
• Weight-corrected CL 0Á087 and 0Á177 L/h•kg in obese and lean rats, respectively (P < 0Á05)
• Significant decline in creatinine clearance from baseline in obese rats coupled with increase in SCr whereas no differences found in lean rats
• • Randomized, crossover study • Median random serum concentrations in patients with BMI ≥ 25 vs. BMI < 25 for IV formulation were 6Á4 and 2Á8 mg/L, respectively (P = 0Á04)
• Increasing serum concentration correlated with increase in ALT levels (P = 0Á85, P = 0Á011 for all concentrations; P = 0Á97, P < 0Á001 for random or trough concentrations)
• 
REVIEW OF ANTIVIRAL AGENTS
Acyclovir
Acyclovir pharmacokinetics in obesity have not been evaluated in animal studies, but there are two case reports and one small human study ( An abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in 1991 described a singledose pharmacokinetics study in obese and non-obese patients. 64 The authors found that V d in both groups was approximately 43 L, leading them to conclude that IBW should be utilized when dosing acyclovir in obesity.
Hernandez et al. 65 describe a 60-year-old obese male (BMI 37Á6 kg/m 2 ) with suspected herpes encephalitis receiving acyclovir at roughly 9 mg/kg/dose ABW IV every 8 h. By day 3, serum creatinine and BUN significantly increased, which prompted a discontinuation of acyclovir. The patient was diagnosed with acyclovir-induced nephrotoxicity and acute renal failure. Efficacy of treatment could not be assessed as herpes encephalitis was ultimately ruled out and the patient was lost to follow-up. Another case report involved a 23-year-old morbidly obese male with suspected viral encephalitis given acyclovir 10 mg/kg/dose ABW IV every 8 h. 66 Within 48 h, renal function deteriorated and acyclovir was discontinued.
Based on recommendations from the manufacturer's prescribing information, as well as these the limited literature, weight-based treatment dosing of acyclovir should be based on IBW. 67 
Cidofovir
Cidofovir pharmacokinetics in obesity have not been evaluated in animal studies, and no published literature in human patients currently exists. The average V d when given with probenecid is 0Á41 L/kg, and <6% of the drug is bound to serum proteins. 68 It is a small drug at 315 Da. No recommendations for dosing in obesity exist in the prescribing information, but pharmacokinetic values in non-obese patients suggest limited distribution into adipose tissue. As a result, decisions regarding the appropriate weight to use when calculating cidofovir dose should be made on a case-by-case basis while balancing risk vs. benefit.
Foscarnet
Foscarnet pharmacokinetics in obesity have not been evaluated in animal or human subjects. It is a small (300 Da), hydrophilic agent and in non-obese adults has a V d of 0Á4-0Á5 L/kg, protein binding of 14-17% and is primarily eliminated via the kidney. 69 Recommendations are not provided in the prescribing information regarding dosing in obese patients. Due to its hydrophilic nature, major risk of nephrotoxicity and other adverse effects, it may be prudent to utilize IBW or AdjBW. • Single-dose pharmacokinetic study
• Acyclovir 5 mg/kg 9
ABW
• Steady-state V d was 0Á74 and 0Á42 L/kg ABW in non-obese and obese patients, respectively
Ganciclovir
Ganciclovir pharmacokinetics in obesity have not been evaluated in animal or human subjects. In non-obese adults, ganciclovir has a steady-state V d of 0Á74 L/kg, and binding to plasma proteins is minimal at 1-2%, which is similar to acyclovir. 70 Dosing in obese patients is not addressed in the prescribing information. Due to the hydrophilic nature of ganciclovir and its similarity in size (277 Da), action and toxicity to acyclovir, utilization of IBW when calculating doses in obese patients could be considered on a case-by-case basis.
UMHS DOSING RECOMMENDATIONS AND COST ANALYSIS
In the summer of 2012, UMHS implemented a weight-based antimicrobial dosing guideline for select antimicrobials in morbidly obese patients ( Table 6 ). The recommendations were developed following extensive literature review and expert opinion for the following antimicrobials: colistimethate, daptomycin, trimethoprim/sulfamethoxazole, acyclovir, foscarnet, ganciclovir and voriconazole. The Pharmacy and Therapeutics Committee approved the guideline, which recommends using AdjBW for patients with BMI ≥35 kg/m 2 for daptomycin, trimethoprim/ sulfamethoxazole, foscarnet, ganciclovir, and voriconazole and IBW when calculating the dose for acyclovir and colistimethate. The recommendations were posted on the internal antimicrobial stewardship website, and pharmacists were provided a copy of the recommendations. Pharmacists were encouraged to recommend dose adjustments for obese patients upon order verification or during daily patient rounds, but there were no prompts built into our computerized physician order entry system during this timeframe.
Compliance with dosing recommendations and cost analysis were performed for all morbidly obese patients (BMI > 35 kg/m 2 ) receiving weight-based dosing of antimicrobials for a 1-year period (November 2012 through November 2013). Compliance with the guideline recommendations occurred in 64% of doses dispensed, which resulted in an annual antimicrobial cost savings of $97 886, based on average wholesale price (Table 7) . If 100% compliance with the guideline was attained, an additional savings potential of $29 733 would be achieved. Efficacy and safety were not evaluated.
WHAT IS NEW AND CONCLUSION
Optimal antimicrobial dosing in obese patients continues to present challenges. Most current publications are pharmacokinetic studies with limited data evaluating clinical efficacy and toxicity. However, morbidly obese patients have altered pharmacokinetic properties for most weight-based antimicrobials compared to normal-weight patients. Providing adjusted-dose weight-based antimicrobial dosing in morbidly obese patients may help maximize efficacy, minimize toxicity and provide antimicrobial cost savings. However, clinical judgment should always be used when making dose adjustments in obese patients, particularly for agents with scarce available literature in obese patients. 
